New concepts for old drugs to maintain sinus rhythm in patients with atrial fibrillation.
Atrial fibrillation (AF) is a chronic, often progressive disease. Despite the ongoing concerted effort to improve AF therapy, often there is no remedy for curing AF and preventing the deleterious effects of the arrhythmia on health. Antiarrhythmic drug therapy is likely to remain the mainstay of therapy for many patients in the foreseeable future. Available antiarrhythmic drugs are moderately effective, which is important for patients who respond, especially given the chronic and often progressive nature of the disease. This article describes emerging concepts under clinical evaluation that attempt to improve the safety of available antiarrhythmic drugs in the treatment of recurrent AF. Two concepts are reviewed: (1) combination of an antiarrhythmic drug with a calcium channel blocker to reduce proarrhythmic side effects, and (2) "intelligent" reduction of the duration of antiarrhythmic drug therapy targeted to periods of symptomatic or likely AF recurrence.
Kirchhof
Paulus
P
Department of Cardiology and Angiology, Hospital of the University of Münster, Münster, Germany. kirchhp@uni-muenster.de
Breithardt
Günter
G
D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D003331:Coronary Vessels / Q000503:physiopathology*; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D013997:Time Factors
D000889:Anti-Arrhythmia Agents